Sell Biocon; target of Rs 330: Motilal Oswal

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Motilal Oswal's research report on Biocon

Biocon (BIOS) reported weak 1QFY18 results. Revenue declined 5% YoY to INR9.3b (est. of INR10b), mainly due to weak performance in the Small molecules (-17% YoY) and Branded formulation s (-13% YoY) segments. With commercialization of the Malaysian plant, operational expense and fixed cost (depreciation and interest cost) increased ~USD12m, leading to a 27% YoY decline in EBITDA to INR1.9b (est. of INR2.3b). Margin for the quarter came in at 20.6% (-530bp YoY), with employee expenses up ~400bp YoY (as % of sales).

Outlook

However, we have increased our TP multiple on the back of enhanced visibility of Biologics launch in the EU and US markets. Maintain Sell with a TP of INR 330 @ 2 3x FY1 9E EPS (v/s INR 300 @ 20 x FY1 9E EPS).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More